SCHEMBL3100534

SCHEMBL3100534

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2cccc(C)c2O)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.43
KAT6A Q92794 4/20 0.43
F2 P00734 3/20 0.42
LARS1 Q9P2J5 1/20 0.41
PLG P00747 3/20 0.39
PLAU P00749 2/20 0.39
KLK1 P06870 2/20 0.39
F10 P00742 1/20 0.39
PLAT P00750 1/20 0.39
KLK5 Q9Y337 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
GAA P10253 1/20 0.38
KLK6 Q92876 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093284 0.94 KAT6A (0.49) KAT6AF2LARS1MEN1KMT2A
SCHEMBL3091891 0.92 F2 (0.43) KAT6AF2LARS1PLGNPC1
SCHEMBL3083932 0.92 F2 (0.43) KAT6AF2LARS1PLGMEN1
SCHEMBL3093039 0.91 MEN1 (0.50) KAT6AF2LARS1PLGKLK1
SCHEMBL15000205 0.90 MEN1 (0.46) KAT6AF2LARS1PLGKLK1
SCHEMBL3100518 0.88 NPC1 (0.51) KAT6AF2LARS1MEN1KMT2A
SCHEMBL3086202 0.88 SMO (0.46) KAT6AF2LARS1MEN1KMT2A
SCHEMBL3101165 0.88 NPC1 (0.51) KAT6AF2LARS1MEN1KMT2A
SCHEMBL3096098 0.88 LARS1 (0.45) KAT6AF2LARS1PLGF10
SCHEMBL3096503 0.88 LARS1 (0.45) KAT6AF2LARS1PLGF10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 KDR 250/4885KAT6A 3337/4885F2 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.